$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000114420413059668 Filed on November 07, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	-$10.39M	$2.284M	$3.724M
YoY Change	-20880.0%	-38.67%	228.98%
Cost Of Revenue	-$3.880M	$1.587M	$2.367M
YoY Change	-428.81%	-32.95%	975.91%
Gross Profit	-$6.520M	$1.772M	$3.023M
YoY Change	476.99%	-41.38%	346.53%
Gross Profit Margin		77.58%	81.18%
Selling, General & Admin	$1.990M	$1.780M	$2.220M
YoY Change	-17.43%	-19.82%	45.1%
% of Gross Profit		100.45%	73.44%
Research & Development		$7.723M	$8.326M
YoY Change		-7.24%	-10.86%
% of Gross Profit		435.84%	275.42%
Depreciation & Amortization	$850.0K	$870.0K	$910.0K
YoY Change	-7.61%	-4.4%	1.11%
% of Gross Profit		49.1%	30.1%
Operating Expenses	$10.58M	$9.503M	$8.326M
YoY Change	17.04%	14.14%	-10.86%
Operating Profit	-$17.10M	-$5.645M	-$5.560M
YoY Change	68.14%	1.53%	-36.58%
Interest Expense	-$740.0K	$119.0K
YoY Change	-355.17%
% of Operating Profit
Other Income/Expense, Net		-$102.0K	$81.00K
YoY Change		-225.93%
Pretax Income	-$17.83M	-$5.750M	-$5.480M
YoY Change	80.47%	4.93%	-38.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$10.89M	-$5.747M	-$5.479M
YoY Change	10.22%	4.89%	-38.26%
Net Earnings / Revenue		-251.62%	-147.13%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.15	-$0.62	-$0.60
COMMON SHARES
Basic Shares Outstanding	93.56M shares	93.54M shares	91.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.40M	$91.40M	$50.20M
YoY Change	66.15%	82.07%	45.09%
Cash & Equivalents	$86.40M	$91.40M	$50.22M
Short-Term Investments
Other Short-Term Assets	$1.457M	$4.200M
YoY Change	-60.62%
Inventory	$7.957M	$7.577M	$2.058M
Prepaid Expenses	$286.0K
Receivables	$2.091M	$2.053M	$4.025M
Other Receivables	$1.457M	$4.173M	$3.281M
Total Short-Term Assets	$97.90M	$105.2M	$59.58M
YoY Change	60.05%	76.57%	47.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.71M	$14.34M	$16.66M
YoY Change	-15.94%	-13.95%	-9.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$1.600M	$1.100M
YoY Change	41.67%	45.45%	-45.0%
Total Long-Term Assets	$15.43M	$15.96M	$17.80M
YoY Change	-12.11%	-10.35%	-13.18%
TOTAL ASSETS
Total Short-Term Assets	$97.90M	$105.2M	$59.58M
Total Long-Term Assets	$15.43M	$15.96M	$17.80M
Total Assets	$113.3M	$121.2M	$77.38M
YoY Change	43.96%	56.58%	27.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.300M	$3.300M	$4.400M
YoY Change	0.0%	-25.0%	-12.0%
Accrued Expenses	$1.785M
YoY Change	-12.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.70M	$25.23M	$20.44M
YoY Change	3.65%	23.45%	11.67%
LONG-TERM LIABILITIES
Long-Term Debt	$2.371M		$2.794M
YoY Change	-56.29%
Other Long-Term Liabilities	$46.50M	$45.70M	$52.20M
YoY Change	-17.41%	-12.45%	-12.85%
Total Long-Term Liabilities	$113.6M	$112.6M	$52.17M
YoY Change	101.64%	115.9%	-12.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.70M	$25.23M	$20.44M
Total Long-Term Liabilities	$113.6M	$112.6M	$52.17M
Total Liabilities	$140.3M	$137.9M	$72.61M
YoY Change	70.9%	89.88%	-7.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$211.4M
YoY Change	15.14%
Common Stock	$184.4M
YoY Change	2.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$26.95M	-$16.71M	$4.772M
YoY Change
Total Liabilities & Shareholders Equity	$113.3M	$121.2M	$77.38M
YoY Change	43.96%	56.58%	27.27%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$10.89M	-$5.747M	-$5.479M
YoY Change	10.22%	4.89%	-38.26%
Depreciation, Depletion And Amortization	$850.0K	$870.0K	$910.0K
YoY Change	-7.61%	-4.4%	1.11%
Cash From Operating Activities	-$4.740M	-$8.210M	-$8.030M
YoY Change	-359.02%	2.24%	-1.47%
INVESTING ACTIVITIES
Capital Expenditures	$220.0K	$330.0K	$770.0K
YoY Change	-12.0%	-57.14%	-21.43%
Acquisitions
YoY Change
Other Investing Activities	-$50.00K	-$90.00K	-$50.00K
YoY Change	-61.54%	80.0%	25.0%
Cash From Investing Activities	-$270.0K	-$420.0K	-$820.0K
YoY Change	-28.95%	-48.78%	-20.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-70.00K	66.93M	-140.0K
YoY Change	-150.0%	-47907.14%
NET CHANGE
Cash From Operating Activities	-4.740M	-8.210M	-8.030M
Cash From Investing Activities	-270.0K	-420.0K	-820.0K
Cash From Financing Activities	-70.00K	66.93M	-140.0K
Net Change In Cash	-5.080M	58.30M	-8.990M
YoY Change	-419.5%	-748.5%	-2.07%
FREE CASH FLOW
Cash From Operating Activities	-$4.740M	-$8.210M	-$8.030M
Capital Expenditures	$220.0K	$330.0K	$770.0K
Free Cash Flow	-$4.960M	-$8.540M	-$8.800M
YoY Change	-413.92%	-2.95%	-3.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93561765	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Trading Symbol TradingSymbol	PLX
	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	15000	USD
	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts		USD
CY2013Q3	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	15000	USD
CY2012Q3	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts		USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	73000	USD
	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	72000	USD
CY2013Q3	plx	Debt Instrument Convertible Base Value For Conversion Rate DebtInstrumentConvertibleBaseValueForConversionRate	1000	USD
CY2013Q3	plx	Debt Instrument Convertible Conversion Share Number DebtInstrumentConvertibleConversionShareNumber	173.6593	shares
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	2689000	USD
	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	2772000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	6049000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	5655000	USD
CY2013Q3	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	2086000	USD
CY2012Q3	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1963000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	187000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	821000	USD
	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
	plx	Other Gains Losses OtherGainsLosses	2275000	USD
	plx	Other Gains Losses OtherGainsLosses	678000	USD
CY2013Q3	plx	Other Gains Losses OtherGainsLosses	1075000	USD
CY2012Q3	plx	Other Gains Losses OtherGainsLosses	1666000	USD
	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses		USD
	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	25328000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	17418000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	22062000	USD
CY2013Q3	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	5637000	USD
CY2012Q3	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6363000	USD
	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts	150000	USD
	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
CY2013Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12400000	USD
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	11051000	USD
CY2013Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3313000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5267000	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2053000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	895000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	4217000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1780000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	15000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7879601	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7169035	shares
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8817090	shares
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7508240	shares
CY2013Q3	us-gaap	Assets Assets	121156000	USD
CY2012Q4	us-gaap	Assets Assets	78727000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	105200000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	61170000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91397000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27001000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50216000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39362000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	23215000	USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	71760000	USD
CY2013Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	66944000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		USD
	us-gaap	Cost Of Revenue CostOfRevenue	3876000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	6966000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	1587000	USD
CY2012Q3	us-gaap	Cost Of Revenue CostOfRevenue	2367000	USD
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.76
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	69000000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.045	pure
CY2013Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-09-15
CY2013Q3	us-gaap	Deferred Costs DeferredCosts	149000	USD
CY2012Q4	us-gaap	Deferred Costs DeferredCosts		USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9513000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9437000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	43419000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48888000	USD
CY2013Q3	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1467000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1247000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.02
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.06
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.06
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	144000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-113000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	140000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-14000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6065000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7353000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1780000	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2220000	USD
	us-gaap	Gross Profit GrossProfit	6515000	USD
	us-gaap	Gross Profit GrossProfit	27410000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	1772000	USD
CY2012Q3	us-gaap	Gross Profit GrossProfit	3023000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5413000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	369000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	798000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2099000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5393000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-4981000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3538000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1779000	USD
	us-gaap	Interest Expense InterestExpense	119000	USD
	us-gaap	Interest Expense InterestExpense		USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	119000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense		USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	104000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		USD
CY2013Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	104000	USD
CY2012Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization		USD
CY2013Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4863000	USD
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1729000	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	7577000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	4039000	USD
CY2013Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2574000	USD
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2118000	USD
CY2013Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	140000	USD
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	192000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	137862000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	82084000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121156000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78727000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25226000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25755000	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	112636000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	56329000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5425000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66960000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26424000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1831000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1910000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25911000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1186000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16905000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1741000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-5747000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-5479000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	63000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	264000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-102000	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	81000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16968000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2005000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5645000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5560000	USD
CY2013Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	4173000	USD
CY2012Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3686000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	121000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	93000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1668000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1817000	USD
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	42000	USD
	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		USD
CY2013Q3	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2273000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2016000	USD
	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	26000	USD
	us-gaap	Pension And Other Postretirement Benefit Contributions PensionAndOtherPostretirementBenefitContributions	24000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	145000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	218000	USD
CY2009Q3	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	66930000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2013Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	66800000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	9000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1096000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14340000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16310000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23467000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27717000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7723000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8326000	USD
	us-gaap	Revenues Revenues	8116000	USD
	us-gaap	Revenues Revenues	33698000	USD
CY2013Q3	us-gaap	Revenues Revenues	2284000	USD
CY2012Q3	us-gaap	Revenues Revenues	3724000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3453000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6065000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-16706000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-26077000	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	4772000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2558000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1848000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25388000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1137000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92307170	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90491421	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92433502	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	91929445	shares

Files In Submission

Name	View Source	Status
0001144204-13-059668-index-headers.html	Edgar Link	pending
0001144204-13-059668-index.html	Edgar Link	pending
0001144204-13-059668.txt	Edgar Link	pending
0001144204-13-059668-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
plx-20130930.xml	Edgar Link	completed
plx-20130930.xsd	Edgar Link	pending
plx-20130930_cal.xml	Edgar Link	unprocessable
plx-20130930_def.xml	Edgar Link	unprocessable
plx-20130930_lab.xml	Edgar Link	unprocessable
plx-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v359133_10q.htm	Edgar Link	pending
v359133_ex31-1.htm	Edgar Link	pending
v359133_ex31-2.htm	Edgar Link	pending
v359133_ex32-1.htm	Edgar Link	pending
v359133_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2013 Q4 Form 10-Q Financial Statement

#000114420413059668 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2013 Q4 Form 10-Q Financial Statement

#000114420413059668 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx